R1 Tx

R1 Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of first-in-class therapies for patients with kidney disease. Its lead programme, AP306, targets hyperphosphatemia in patients with chronic kidney disease on dialysis. AP306 is a first-in-class pan phosphate active transport inhibitor designed to block three key phosphate transporters in the gut, with the potential to deliver rapid and effective phosphorus lowering with a significantly reduced treatment burden.